nach oben

Erschienen in:

Open Access 01.12.2015 | Research article

Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer

verfasst von: Takuro Yamamoto, Taisuke Mori, Morio Sawada, Hiroshi Matsushima, Fumitake Ito, Makoto Akiyama, Jo Kitawaki

Erschienen in: BMC Cancer | Ausgabe 1/2015

Abstract

Background

AF-6/afadin plays an important role in the formation of adherence junctions. In breast and colon cancer, loss of AF-6/afadin induces cell migration and cell invasion. We aimed to elucidate the role of AF-6/afadin in human endometrial cancer.

Methods

Morphology and AF-6/afadin expression in endometrial cancer cell lines was investigated by 3-dimensional culture. We used Matrigel invasion assay to demonstrate AF-6/afadin knockdown induced invasive capability. Cell proliferation assay was performed to estimate chemoresistance to doxorubicin, paclitaxel and cisplatin induced by AF-6/afadin knockdown. The associations between AF-6/afadin expression and clinicopathological status were determined by immunohistochemical analysis in endometrial cancer tissues. Informed consent was obtained from all patients before the study.

Results

The majority of cell clumps in 3-dimensional cultures of Ishikawa cells that strongly expressed AF-6/afadin showed round gland-like structures. In contrast, the cell clumps in 3-dimensional cultures of HEC1A and AN3CA cells—both weakly expressing AF-6/afadin—showed irregular gland-like structures and disorganized colonies with no gland-like structures, respectively. AF-6/afadin knockdown resulted in reduced number of gland-like structures in 3-dimensional cultures and enhancement of cell invasion and phosphorylation of ERK1/2 and Src in the highly AF-6/afadin-expressing endometrial cancer cell line. Inhibitors of MAPK/ERK kinase (MEK) (U0126) and Src (SU6656) suppressed the AF-6/afadin knockdown-induced invasive capability. AF-6/afadin knockdown induced chemoresistance to doxorubicin, paclitaxel and cisplatin in Ishikawa cells, not in HEC1A. Immunohistochemical analysis showed that AF-6/afadin expression was significantly associated with myometrial invasion and high histological grade.

Conclusions

AF-6/afadin regulates cell morphology and invasiveness. Invasive capability is partly regulated through the ERK and Src pathway. The inhibitors to these pathways might be molecular-targeted drugs which suppress myometrial invasion in endometrial cancer. AF-6/afadin could be a useful selection marker for fertility-sparing therapy for patients with atypical hyperplasia or grade 1 endometrioid adenocarcinoma with no myometrial invasion. AF-6/afadin knockdown induced chemoresistance especially to cisplatin. Therefore, loss of AF-6/afadin might be a predictive marker of chemoresistance to cisplatin.

Takuro Yamamoto and Taisuke Mori contributed equally to this work.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

TY conceived the study, carried out all the experiments and drafted the manuscript. TM conceived the study, participated in the design of the study, helped to draft the manuscript and acted as a corresponding author. MS carried out the immunohistochemical analysis. HM participated in the design of the study and carried out the invasion assay. FI participated in the design of the study and performed the statistical analysis. MA participated in the design of the study and carried out immunohistochemical analysis. JK supervised research projects and revised the manuscript. All authors read and approved the final manuscript.

Three-dimensional

EMT

Epithelial-mesenchymal transition

Knockdown

PFS

Progression-free survival

Overall survival

FBS

Fetal bovine serum

siRNA

Short interfering RNA

Background

Endometrial cancer is one of the most common gynecological malignancies and its incidence has increased remarkably [1,2]. Endometrial cancers are broadly classified into two groups: (1) Type 1 disease, the most common type of endometrial cancer, is estrogen-related, low-grade, histologically endometrioid adenocarcinoma in most cases and shows minimal myometrial invasion and occurs at a younger age. (2) Type 2 disease is high-grade, histologically serous or clear cell adenocarcinoma and shows deep myometrial invasion [3].

Cell polarity and cell-cell adhesion are essential for normal functioning of epithelial tissues. In cancer, the epithelial-mesenchymal transition (EMT) is a process where epithelial cells detach from primary tumors, invade into the surrounding tissues, metastasize, and grow at a secondary site [4]. Cell-cell junctions are lost in EMT. Most patients present with low-grade and early-stage endometrial cancer. However, once the disease spreads beyond the uterus, the prognosis is poor, and the 5-year survival is 25–45% for stage III and IV [5]. Therefore, it is essential to decrease tumor invasiveness for the treatment of endometrial cancer.

AF-6/afadin is encoded by the MLLT4 gene located on chromosome 6, band q27 [6]. AF-6/afadin binds to nectins, plays important cooperative roles in the formation of adherens junctions, and is associated with the actin cytoskeleton [7]. It is also important for cell polarity at cell-cell junctions [8,9]. Conversely, AF-6/afadin at the leading edge does not bind nectins, and enhances cell movement [10]. Thus, AF-6/afadin has conflicting role in cell invasion. AF-6/afadin loss induces cell migration, invasion, and proliferation, and is a prognostic indicator in breast and colon cancer [11-14]. However, its role and expression in endometrial cancer have not been studied. In this study, we investigate for the first time the expression of AF-6/afadin in patients with endometrial cancer and its role in cell invasion and chemoresistance in endometrial cancer.

Methods

Cell lines and materials

The Ishikawa line of human uterine endometrial cancer cells was provided by the Cell Resource Center for Biomedical Research (Institute of Development, Aging and Cancer, Tohoku University, Japan). The HEC1A and AN3CA cells were purchased from the American Type Culture Collection. The Ishikawa and AN3CA cells were maintained in Eagle’s MEM (Nacalai Tesque, Kyoto, Japan) with nonessential amino acids, sodium pyruvate, and 10% fetal bovine serum (FBS) (Invitrogen Corp., Carlsbad, CA). The HEC1A cells were maintained in McCoy’s 5A (HyClone, Logan, UT) with sodium pyruvate, supplemented with 10% FBS. We focused on endometrioid adenocarcinoma because it was the major type observed, and the histological grade and myometrial invasion are important for its diagnosis and treatment. All patient samples used for this study were obtained from University hospital, Kyoto Prefectural University. The Kyoto Prefectural University of Medicine human research ethics board approved all protocols and patients gave informed consent.

RNA isolation and quantitative PCR analysis

Total RNA (1 μg) was isolated from the cells, 24 or 48 h after siRNA transfection, using the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Each cDNA was synthesized from 1 μg RNA using the ReverTra Ace qPCR RT kit (Toyobo, Osaka, Japan). Real-time reverse transcription-PCR was carried out using the CFX Connect™ Real-Time System (Bio-Rad, Hercules, CA). cDNA samples prepared from the total RNA of Ishikawa, HEC1A, and AN3CA cells (1 μL) were mixed in 20-μL reactions containing SYBR qPCR Thunderbird master mix (Toyobo, Osaka, Japan) and 0.2 μmol/L of each primer. Primers, AF-6/afadin 5′-GTGGGACAGCATTACCGACA-3′ (forward) and 5′-TCATCGGCTTCACCATTCC-3′ (reverse) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 5′-GCACCGTCAAGGCTGAGAAC-3′ (forward) and 5′-ATGGTGGTGAAGACGCCAGT-3′ (reverse) were designed with Primer 3 software. The amplification, detection, and data analysis were performed using the CFX Connect™ Real-Time System. Each sample was analyzed in triplicate. The expression levels of genes were determined relative to the expression level of GAPDH.

RNA interference

Small interfering RNAs (siRNA) for MLLT4/AF-6 (s8829, s8830 and s8831) and a negative control siRNA (control #1) targeting no known genes were Silencer® Select siRNAs purchased from Ambion (Austin, TX). Cells were transfected with the siRNA using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions, and used for each experiment after 24 or 48 h. AF-6/afadin KD effects were measured with real-time PCR and western blotting. We decided to use siRNA for AF-6/afadin (s8830) for the following experiments, because it has the strongest KD activity of the validated siRNAs.

Three-dimensional cell culture

Cells (2.5 × 10⁵) from the Ishikawa, HEC1A, and AN3CA lines were trypsinized and suspended in 800 μL of BD Matrigel™ Matrix Basement Membrane (BD biosciences, Bedford, MA), as previously described [15]. The paraffin-embedded specimens were cut into 3.5-μm sections for hematoxylin-eosin staining and AF-6/afadin immunohistochemical staining. Each experiment was performed three times.

Matrigel invasion assay

Cells (2.0 × 10⁵) were seeded into the top of a Matrigel invasion chamber (24-well insert; pore size, 8 μm; BD Biosciences, Bedford, MA) containing a serum-free and a medium with 10% FBS was used as a chemoattractant in the lower chamber. The cells were incubated for 48 h at 37°C. A cotton swab was used to remove the cells, that did not invade through the pore and cells that had migrated to the lower surface of the membrane were stained with the Diff-Quik kit (Sysmex, Kobe, Japan) and counted.

Cell proliferation assay

Cells (5.0 × 10³) were seeded into 96-well plates containing a normal growth medium, and RNA interference was performed after 24 h. The anticancer drugs were added at various doses, 24 h after siRNA transfection. The cells were cultured and treated in quadruplicate, and cell viability was examined after 72 h by the 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphonyl)-2H-tetrazolium (WST-8) assay (Nacalai Tesque, Kyoto, Japan).

Antibodies

A mouse anti-AF-6/afadin antibody (clone 35) was purchased from Becton Dickinson. A mouse anti-Src antibody (# 2110) and rabbit anti-GAPDH (# 2118), anti-ERK1/2 (# 9102), anti-phospho-ERK1/2 (Thr202/Tyr204), and anti-phospho-Src family (Tyr416) (# 2101) antibodies were purchased from Cell Signaling Technology (Beverly, MA). All antibodies were used at the concentration recommended by the manufacturers.

Western blotting

Cells were washed twice in phosphate-buffered saline and lysed in RIPA buffer (Nacalai Tesque, Kyoto, Japan).

Cell lysates (20 μg) were heated in sodium dodecyl sulfate (SDS) sample buffer (125 mM Tris–HCl, pH 6.8, 4% SDS, 25% glycerol, 10% 2-mercaptoethanol, 0.05 mM phenylmethanesulfonyl fluoride and 0.004% bromophenol blue), separated using 10% e-PAGEL according to the manufacturer’s recommendations (Atto Corp, Tokyo, Japan), and transferred onto Immuno-Blot® PVDF membranes (Bio-Rad, Hercules, CA). The membranes were blocked in Tris-buffered saline supplemented with 5% fat-free milk for 1 h and then incubated with indicated antibodies at 4°C overnight. After washing, the membranes were incubated with the secondary antibody for 1 h at room temperature. The signal was developed using Chemi-Lumi One Super (Nacalai Tesque, Kyoto, Japan) and analyzed by a ChemiDoc XRS system with Image Lab software (Bio-Rad, Hercules, CA).

Immunohistochemistry

Specimens from patients who underwent abdominal hysterectomy because of uterine endometrial cancer were used for this study. Informed consent was obtained from all the patients before the study was conducted. The protocol has been previously described [16]. The AF-6/afadin immunoreactivities were scored using a semiquantitative index, the H-score. The H-score is the product of the intensity of staining (given a value of 0, 1, 2, or 3 for negative, weak, moderate, or strong, respectively) and the percentage of stained epithelial cells at each intensity (0–100%). Samples with H-score ≥ 50 were deemed as AF-6/afadin-positive.

Statistical analysis

Progression-free survival and overall survival were assessed using the Kaplan-Meier method and log-rank test. Comparisons of the means and standard error of data between two groups were performed using the Student’s t test. Comparisons of over 3 groups were performed using the Kruskal-Wallis H-test, and the Mann–Whitney U-test with Bonfferoni correction was as a post hoc test. Statistical differences between AF-6/afadin status and histological type, histological grade, myometrial invasion, lymph node status, and stage were evaluated using a chi-square test. P values < 0.05 were considered significant.

Results

Low expression levels of AF-6/afadin in uterine endometrial cancer tissues were associated with myometrial invasion and high histological grade

All sections of normal endometrium stained positive for AF-6/afadin. AF-6/afadin was expressed in the cytoplasm and at the surface of the epithelial cells. The association between AF-6/afadin immunoreactivity and clinicopathological status are shown in Table 1. Of the 90 endometrial cancer cases, 85 cases were endometrioid adenocarcinomas.

Table 1

Association between AF-6/afadin immunoreactivity and clinicopathological parameters in 90 uterine endometrial cancers

AF-6/afadin immunoreactivity
Uterine endometrial cancer	Positive (n = 51)	Negative (n = 39)	Pvalue
Mean age (range)	55.9 (32–83)	58.6 (28–80)	0.41
Histological type
Endometrioid	51 (100%)	34 (87.2%)
Serous	0	3 (7.7%)
Clear	0	2 (5.1%)	0.21
Endometrioid adenocarcinoma	Positive (n = 51)	Negative (n = 34)	P value
Histological grade
1	38 (74.5%)	11 (32.4%)
2	11(21.6%)	13(38.2%)
3	2 (3.9%)	10 (29.4%)	P < 0.01
Myometrial invasion
No invasion	14 (27.5%)	1 (2.9%)
Less than half	26 (51.0%)	15 (44.1%)
More than half	11 (21.6%)	18 (52.9%)	P < 0.01
Lymph node metastasis
Negative	48 (94.1%)	30 (88.2%)
Positive	3 (5.9%)	4 (11.8%)	0.57
Stage
I	37 (72.5%)	25 (73.5%)
II	7 (13.7.8%)	2 (5.9%)
III	6 (11.8%)	6 (17.6%)
IV	1 (2.0%)	1 (2.9%)	0.82

Cases with H-score > 50 are positive.

The H-score of AF-6/afadin was significantly associated with histological grade (between grade 1 and 2 cases, and between grade 1 and 3 cases, P < 0.01) and myometrial invasion (between cases with no invasion and cases with a myometrial invasion depth of more than 50%, P < 0.01) in endometrioid adenocarcinoma (Figure 1b, c). The H-score of the normal endometrium (n =10) was significantly higher than that of the endometrioid adenocarcinoma (between normal endometrium and grade 1, P < 0.05, and between normal endometrium and grade 2, and 3, P < 0.01) (Figure 1b). However, there were no significant associations between the AF-6/afadin immunoreactivity and the FIGO stage, lymph node metastasis, progression-free survival (PFS), or overall survival (OS) (P = 0.18 and 0.21 for PFS and OS, respectively).

AF-6/afadin plays an important role in 3-dimensional cultures of Ishikawa, HEC1A, and AN3CA cells

To investigate AF-6/afadin expression and morphology, 3-dimensional (3D) culture was performed. AF-6/afadin mRNA level in 3D cultures was significantly higher than that in monolayer cultures in Ishikawa cells (P < 0.01), similar to that in monolayer cultures in the HEC1A, and significantly lower than that in monolayer cultures in AN3CA cells (P < 0.01) (Figure 2a). AF-6/afadin immunostaining was strongly, weakly, and very weakly positive in the Ishikawa, HEC1A, and AN3CA cells, respectively. The majority of the cell clumps in 3D cultures of Ishikawa cells showed round gland-like structures, whereas the cell clumps in 3D cultures of HEC1A and AN3CA showed irregular gland-like structures and disorganized colonies with no gland-like structures, respectively (Figure 2b). RNA interference experiments to knockdown (KD) AF-6/afadin and subsequent 3D cultures were performed using the Ishikawa cells. In this assay, paraffin specimens were prepared on day 5 when the AF-6/afadin KD was still maintained. AF-6/afadin KD increased the number of disorganized colonies and reduced the number of gland-like structures in 3D cultures of Ishikawa cells (P < 0.01) (Figure 3).

AF-6/afadin KD induced phosphorylation of ERK1/2 and Src kinase and stimulated cell invasion in AF-6/afadin-positive cell lines

First, we evaluated whether AF-6/afadin regulates cell migration and invasion in endometrial cancer, using trans-well cell culture inserts and the Matrigel Invasion chamber system. We used Ishikawa (AF-6/afadin strong positive) cells and HEC1A (AF-6/afadin weak positive) cells. AF-6/afadin KD cells significantly enhanced the invasive capability in the Ishikawa and HEC1A compared with negative control cells (P < 0.05) (Figure 4a-d); however, although the migratory capability was examined using Trans-well cell culture inserts without Matrigel coating, it remained unchanged (data not shown).

We next investigated how AF-6/afadin KD stimulates invasive capability. In Ishikawa cells, AF-6/afadin KD induced phosphorylation of ERK1/2 and Src kinases. Conversely, in HEC1A cells, ERK1/2 and Src kinase were already activated and AF-6/afadin KD did not significantly increase the level of phosphorylated ERK1/2 or Src (Figure 4e). This result indicates that AF-6/afadin functions as a suppressor of ERK and Src phosphorylation pathways. Using the MEK inhibitor (U0126) and the Src kinase inhibitor (SU6656), we demonstrated the importance of ERK1/2 and Src phosphorylation for regulating the cell invasion induced in the Ishikawa cells by AF-6/afadin KD. First, we determined the concentrations of U0126 and SU6656 (5 μM and 1 μM, respectively). At the determined concentrations, the reagents inhibited phosphorylation of ERK1/2 and Src, and did not influence the proliferation of the Ishikawa cells (data not shown). At these concentrations, U0126 and SU6656 significantly inhibited Ishikawa cell invasions induced by AF-6/afadin KD (Figure 5). This result indicates that AF-6/afadin KD induced cell invasion through ERK and Src signaling pathways.

AF-6/afadin KD induced chemoresistance to doxorubicin, paclitaxel and cisplatin in AF-6/afadin strongly positive cell line

To estimate chemoresistance to doxorubicin, paclitaxel and cisplatin induced by AF-6/afadin KD, we performed the WST-8 assay cell proliferation assay using. In Ishikawa cells, AF-6/afadin KD induced slight chemoresistance to doxorubicin and paclitaxel, and strong resistance to cisplatin (Figure 6a-c, respectively). However, AF-6/afadin did not induce chemoresistance in HEC1A cells (Figure 6d-e).

Discussion

AF-6/afadin is expressed in almost all normal epithelial tissues where it is involved in forming the actin cytoskeleton by binding actin filaments and nectins (immunoglobulin-like cell adhesion molecules) [17]. AF-6/afadin, in cooperation with nectins, involved in the formation of a variety E-cadherin-dependent or E-cadherin-independent cell-cell junctions [7,9,18,19]. Decreased E-cadherin expression is associated with poor prognosis, high histological grade and advanced stage in endometrial cancer [20-22]. Immunohistochemical analysis revealed that AF-6/afadin expression in endometrial cancer tissues was lower than that in normal endometrial tissues. Furthermore, loss of AF-6/afadin expression was associated with myometrial invasion and high histological grade in patients with endometrial cancer.

Three-dimensional cell culture is a useful model to investigate molecular signaling and cellular behavior during epithelial morphogenesis [23]. In this study, when comparing the mRNA levels in monolayer and 3D cultures, the mRNA levels of nectins in both cultures were found to be similar, while AF-6/afadin mRNA levels in well-differentiated and poorly differentiated endometrial cancer cell lines were higher and lower, respectively, in the 3D cultures. These results suggest that AF-6/afadin could be an important scaffold protein determining epithelial morphogenesis in uterine endometrial cancer.

AF-6/afadin was strongly expressed in Ishikawa cells, a well-differentiated and grade 1 equivalent endometrial adenocarcinoma cell line, whereas AF6/afadin was weakly expressed in HEC1A and AN3CA cells, which are derived from grade 2 and grade 3 endometrial adenocarcinomas, respectively. In 3D cultures, AF-6/afadin expression was positively associated with the formation of round gland-like structures. AF-6/afadin was expressed in all normal endometrial tissues and most well-differentiated endometrial adenocarcinomas in our study. Therefore, we investigated the function of AF-6/afadin using an RNA interference assay. In endometrioid cancers, histological grade is defined in terms of solid tumor growth; increased solid growth is associated with high histological grade and a high degree of cellular atypia [24]. AF-6/afadin KD resulted in fewer gland-like structures and more disorganized colonies in Ishikawa cell cultures than in the KD control cultures. This result explains why AF-6/afadin loss was associated with higher histological grade. AF-6/afadin KD significantly enhanced cell invasion in AF-6/afadin-positive endometrial cancer cell lines. These results suggest that AF-6/afadin serves as a positive regulator of duct formation and as an inhibitor of tissue invasion in human endometrial cancer.

We focused on the cell signaling pathways induced by AF-6/afadin KD to determine the mechanisms underlying these findings. A Src signaling is important in multiple physiological homeostatic pathways that regulate cell proliferation, cell survival, cytoskeleton regulation, intracellular contacts, cell-matrix adhesion, motility, and migration [25,26]. An Src mutation at codon 537 was previously detected in a small subset of endometrial cancers [27]. In this study, we demonstrated that enhancement of phosphorylation in the Src kinase family was induced by AF-6/afadin KD in the strongly AF-6/afadin-positive Ishikawa cells. The AF-6/afadin KD-induced invasiveness of the Ishikawa cells was repressed by SU6656, an Src inhibitor. These findings indicate that AF-6/afadin might regulate cell invasion through the Src signaling pathway.

RAS/RAF/MEK/ERK pathways are also important for cell proliferation and survival in several cancers [28-33]. AF-6/afadin links to Bcr and RAS and down-regulates RAS-dependent stimulation of the RAF/MEK/ERK signaling pathway [34]. The activation of ERK1/2 induced by AF-6/afadin KD has been reported in breast cancer [12]. We also found that AF-6/afadin KD increased phosphorylation of ERK1/2 proteins. In addition, U0126, a MEK inhibitor, also suppressed AF-6/afadin KD induced phosphorylation of ERK1/2 and cell invasion in endometrial cancer. These results also suggest that AF-6/afadin KD induced cell invasion through the RAF/MEK/ERK signaling pathway.

Chemoresistance is an important problem in cancer therapy. The ERK pathway has been implicated in chemoresistance to doxorubicin, paclitaxel and cisplatin in some cancers [35-39], although the findings are controversial. AF-6/afadin KD increased the phosphorylation of ERK 1/2 in Ishikawa cells, but not in HEC1A cells. AF-6/afadin KD also induced chemoresistance to doxorubicin, paclitaxel, and cisplatin in AF-6/afadin strongly positive Ishikawa cells. These results suggest that the ERK pathway could be involved in the chemoresistance induced by AF-6/afadin KD.

Conclusions

In this study, we demonstrated that AF-6/afadin regulates cell invasion through ERK and Src pathway. The inhibitors to these pathways might be molecular-targeted drugs which suppress myometrial invasion in endometrial cancer. AF-6/afadin is an important scaffold protein and might be crucial for maintenance of the ductal structure of glands in the endometrium. Reduced expression of AF-6/afadin is associated with high histological grade and myometrial invasion of endometrial cancers. AF-6/afadin could be a useful selection marker for fertility-sparing therapy for the patients with atypical hyperplasia or grade 1 endometrioid adenocarcinoma with no myometrial invasion. AF-6/afadin KD induced strong chemoresistance to cisplatin. Therefore, loss of AF-6/afadin might be a predictive marker of chemoresistance to cisplatin.

Acknowledgement

This study was supported by Grant-in-Aid for scientific research (no.23791849) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Aoki D. Annual report of gynecologic oncology committee, Japan society of obstetrics and gynecology, 2013. J Obstet Gynaecol Res. 2014;40(2):338–48.CrossRefPubMed

Ushijima K. Current status of gynecologic cancer in Japan. J Gynecol Oncol. 2009;20(2):67–71.CrossRefPubMedPubMedCentral

Sorosky JI. Endometrial cancer. Obstet Gynecol. 2008;111(2 Pt 1):436–47.CrossRefPubMed

Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1–2):15–33.CrossRefPubMed

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491–505.CrossRefPubMed

Saha V, Lillington DM, Shelling AN, Chaplin T, Yaspo ML, Ganesan TS, et al. AF6 gene on chromosome band 6q27 maps distal to the minimal region of deletion in epithelial ovarian cancer. Genes Chromosomes Cancer. 1995;14(3):220–2.CrossRefPubMed

Takahashi K, Nakanishi H, Miyahara M, Mandai K, Satoh K, Satoh A, et al. Nectin/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein. J Cell Biol. 1999;145(3):539–49.CrossRefPubMedPubMedCentral

Asakura T, Nakanishi H, Sakisaka T, Takahashi K, Mandai K, Nishimura M, et al. Similar and differential behaviour between the nectin-afadin-ponsin and cadherin-catenin systems during the formation and disruption of the polarized junctional alignment in epithelial cells. Genes Cells. 1999;4(10):573–81.CrossRefPubMed

Takai Y, Nakanishi H. Nectin and afadin: novel organizers of intercellular junctions. J Cell Sci. 2003;116(Pt 1):17–27.CrossRefPubMed

10.

Miyata M, Ogita H, Komura H, Nakata S, Okamoto R, Ozaki M, et al. Localization of nectin-free afadin at the leading edge and its involvement in directional cell movement induced by platelet-derived growth factor. J Cell Sci. 2009;122(Pt 23):4319–29.CrossRefPubMed

11.

Elloul S, Kedrin D, Knoblauch NW, Beck AH, Toker A. The Adherens Junction Protein Afadin Is an AKT Substrate that Regulates Breast Cancer Cell Migration. Mol Cancer Res. 2014.

12.

Fournier G, Cabaud O, Josselin E, Chaix A, Adelaide J, Isnardon D, et al. Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. Oncogene. 2011;30(36):3862–74.CrossRefPubMed

13.

Sun TT, Wang Y, Cheng H, Zhang XH, Xiang JJ, Zhang JT, et al. Disrupted interaction between CFTR and AF-6/afadin aggravates malignant phenotypes of colon cancer. Biochim Biophys Acta. 2013;1843(3):618–28.CrossRef

14.

Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F, et al. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene. 2007;26(2):298–307.CrossRefPubMed

15.

Koshiba H, Hosokawa K, Kubo A, Tokumitsu N, Watanabe A, Honjo H. Junctional adhesion molecule A [corrected] expression in human endometrial carcinoma. Int J Gynecol Cancer. 2009;19(2):208–13.CrossRefPubMed

16.

Yamamoto T, Mori T, Sawada M, Kuroboshi H, Tatsumi H, Yoshioka T, et al. Estrogen-related receptor-gamma regulates estrogen receptor-alpha responsiveness in uterine endometrial cancer. Int J Gynecol Cancer. 2012;22(9):1509–16.PubMed

17.

Mandai K, Nakanishi H, Satoh A, Obaishi H, Wada M, Nishioka H, et al. Afadin: A novel actin filament-binding protein with one PDZ domain localized at cadherin-based cell-to-cell adherens junction. J Cell Biol. 1997;139(2):517–28.CrossRefPubMedPubMedCentral

18.

Ooshio T, Irie K, Morimoto K, Fukuhara A, Imai T, Takai Y. Involvement of LMO7 in the association of two cell-cell adhesion molecules, nectin and E-cadherin, through afadin and alpha-actinin in epithelial cells. J Biol Chem. 2004;279(30):31365–73.CrossRefPubMed

19.

Sato T, Fujita N, Yamada A, Ooshio T, Okamoto R, Irie K, et al. Regulation of the assembly and adhesion activity of E-cadherin by nectin and afadin for the formation of adherens junctions in Madin-Darby canine kidney cells. J Biol Chem. 2006;281(8):5288–99.CrossRefPubMed

20.

Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004;10(16):5546–53.CrossRefPubMed

21.

Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R, Prat J, et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol. 2003;199(4):471–8.CrossRefPubMed

22.

Gonzalez-Rodilla I, Aller L, Llorca J, Munoz AB, Verna V. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer. Anticancer Res. 2013;33(11):5091–5.PubMed

23.

O’Brien LE, Zegers MM, Mostov KE. Opinion: Building epithelial architecture: insights from three-dimensional culture models. Nat Rev Mol Cell Biol. 2002;3(7):531–7.CrossRefPubMed

24.

Mariani A, Dowdy SC, Podratz KC. New surgical staging of endometrial cancer: 20 years later. Int J Gynaecol Obstet. 2009;105(2):110–1.CrossRefPubMed

25.

Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513–609.CrossRefPubMed

26.

Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6):470–80.CrossRefPubMed

27.

Sugimura M, Kobayashi K, Sagae S, Nishioka Y, Ishioka S, Terasawa K, et al. Mutation of the SRC gene in endometrial carcinoma. Jpn J Cancer Res. 2000;91(4):395–8.CrossRefPubMed

28.

Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 2000;79(3):355–69.CrossRefPubMed

29.

Li C, Ahlborn TE, Kraemer FB, Liu J. Oncostatin M-induced growth inhibition and morphological changes of MDA-MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway. Breast Cancer Res Treat. 2001;66(2):111–21.CrossRefPubMed

30.

Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama M, Sawatari T, et al. The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer. 2001;92(1):55–62.CrossRefPubMed

31.

Kanai M, Konda Y, Nakajima T, Izumi Y, Kanda N, Nanakin A, et al. Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene. 2003;22(4):548–54.CrossRefPubMed

32.

Koochekpour S, Sartor O, Lee TJ, Zieske A, Patten DY, Hiraiwa M, et al. Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells. Prostate. 2004;61(2):114–23.CrossRefPubMed

33.

Nguyen TT, Tran E, Nguyen TH, Do PT, Huynh TH, Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis. 2004;25(5):647–59.CrossRefPubMed

34.

Radziwill G, Erdmann RA, Margelisch U, Moelling K. The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain. Mol Cell Biol. 2003;23(13):4663–72.CrossRefPubMedPubMedCentral

35.

Chen T, Wang C, Liu Q, Meng Q, Sun H, Huo X, et al. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Cancer Biol Ther. 2015;16(1):106–14.CrossRefPubMed

36.

Wu G, Qin XQ, Guo JJ, Li TY, Chen JH. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 2014;7(4):1449–58.PubMedPubMedCentral

37.

Fu X, Feng J, Zeng D, Ding Y, Yu C, Yang B. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/Erk-dependent pathways. Biosci Rep. 2014;34(2):art:e00094.CrossRef

38.

Wang J, Zhou JY, Wu GS. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res. 2007;67(24):11933–41.CrossRefPubMed

39.

Wu DW, Wu TC, Wu JY, Cheng YW, Chen YC, Lee MC, et al. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression. Oncogene. 2014;33(35):4385–95.CrossRefPubMed

Titel: Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer
verfasst von: Takuro Yamamoto
Taisuke Mori
Morio Sawada
Hiroshi Matsushima
Fumitake Ito
Makoto Akiyama
Jo Kitawaki
Publikationsdatum: 01.12.2015
Verlag: BioMed Central
Erschienen in: BMC Cancer / Ausgabe 1/2015
Elektronische ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1286-x

Springer Medizin

Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer